Rarity Bioscience is headed to the Biomarkers 2024 UK!

Rarity Bioscience is headed to the Biomarkers 2024 UK conference in London, to present how the superRCA technology expands the possibilities of Biomarkers and Liquid Biopsies.  Join Us. Join the Discussion.  Biomarkers 2024 UK, London Date: 29 Feb – 01 Mar Poster: ”Non-invasive patient stratification and treatment follow-up using ctDNA in Colorectal cancer patients” Book […]

Rarity Bioscience is presenting the superRCA technology at ESH Conference!

Rarity Bioscience will be at the ESH 4th How to Diagnose and Treat Acute Leukaemias Conference to present the poster ”New Assay Technology and Utility of Peripheral Blood vs Bone Marrow for Molecular MRD in AML and MDS”.  ESH 4th How to Diagnose and Treat Acute Leukaemias March 1st – 3rd, 2024 – Stockholm, Sweden […]

Linus Bosaeus, CEO at Rarity Bioscience, on cutting-edge MRD mutation detection at ASH Annual Meeting 2023

Download the presentation here Linus Bosaeus, CEO at Rarity Bioscience, entered the ASH Annual Meeting 2023 for an interesting conference, delving into advancements in Hematologic Cancer detection and the latest developments in Minimal Residual Disease (MRD) Monitoring. Additionally, he shared insights on the superRCA technology and its potential impacts on molecular MRD and blood analysis, […]

Scientific workshop on superRCA at ASH 2023 with Lei Chen CTO at Rarity Bioscience


Based on an award-winning presentation. Lei Chen, co-founder and CTO at Rarity Bioscience, presents at the ASH Annual Meeting 2023! He will host a scientific workshop expanding on Molecular MRD and the superRCA technology: “Ultra-Sensitive Molecular MRD on Flow Cytometer Using superRCA Mutation Assay”. In the upcoming workshop, you will gain insights into the superRCA […]

Blood or Marrow? MRD poster presented at ESH AML Conference

Click Here to Download the MRD Poster Rarity Bioscience’s Alexander Kele and Ann-Sofi Johansson attended the biannual ESH AML Conference, in Estoril (Portugal). They were there not only to discuss MRD testing but also to support the poster presentation “Utility of Blood vs Bone marrow for molecular MRD in AML and MDS”.  Anna Robelius presenting […]


Download the full presentation Our own CTO, Lei Chen, held an award winning presentation at ESCCA 2023 in Utrecht, “Ultra-sensitive molecular MRD on flow cytometer using superRCA mutation assay”. In the presentation you can see results of testing AML patients using FCM, NGS, ddPCR and Rarity Biosciences ultra-sensitive superRCA. The presentation also suggests why Flow-MRD and superRCA molecular-MRD […]

Rarity Bioscience nominated for ESCCA Best Abstract Award

Read the full abstract here We are thrilled to share that Rarity Bioscience together with Karolinska Institutet and Uppsala University are nominated to the ESCCA Best Abstract Award, for the abstract “Ultra-sensitive molecular MRD on flow cytometer using superRCA mutation assay.”. A spart of that we have been awarded a plenary session presentation. Come and […]

Multiplex KRAS superRCA assays

Rarity offers ultra-sensitive and multiplexed mutation detection on 21 of the most common KRAS hotspot mutations for liquid biopsy research. To see our Multiplex KRAS superRCA assays, and explore all our assays: Go to our assays here! Analyzing KRAS mutations in cancer is crucial for understanding the underlying mechanisms of tumor growth. These mutations, prevalent […]

Rarity Bioscience Achieves ISO 13485 Quality System Certification

We can now proudly announce that Rarity Bioscience have achieved the ISO 13485:2016 certification from BSI! The achievement emphasizes Rarity Bioscience’s commitment to becoming a trusted and reliable partner in research, diagnostics, and therapeutics. Attaining this certification sets Rarity Bioscience apart from other early stage biotech startups in the rapidly evolving field of diagnostics. ”This certification […]